Trial | NCT00123916  Report issue

Title

BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    benznidazole ...

  • Study Participants

    2854
Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC).

The BENEFIT study is being conducted by the Population Health Research Institute (in Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil) together with a Steering Committee, and an independent Safety Monitoring Board.
A randomized double-blind controlled clinical trial investigating the role of benznidazole in patients with chronic Chagas' heart disease.

Chagas disease has 3 phases: acute, undetermined and chronic phases. There are no clinical trials up to date that have investigated the use of antiparasitic drugs in patients that are in the chronic phase.

This study will evaluate the efficacy and safety of benznidazole (an antiparasitic drug) in patients with chronic Chagas' heart disease. Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC). It will be developed in 49 study centres in Argentina, Bolivia,Brazil,Colombia, and El Salvador - countries with high incidence of Chagas Disease.

The Pilot study is evaluating if benznidazole is effective in producing parasitic cure (PCR negativization or reducing parasitic load) in chronic Chagas Disease as well as assessing the feasibility of conducting a large trial in chronic Chagas Disease in South America.
Study Started
Nov 30
2004
Primary Completion
Jul 31
2015
Study Completion
Aug 31
2015
Last Update
Mar 03
2020

Drug Benznidazole

Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)

  • Other names: Rochagan/LaFepe

Drug Placebo

a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)

  • Other names: Rochagan/LaFepe

Benznidazole Experimental

40 - 80 days (according to body weight) treatment with benznidazol

Placebo Placebo Comparator

40 - 80 days (according to body weight) treatment with matching placebo

Criteria 

Inclusion Criteria:

Consenting patients (between 18 and 75 years of age) with serological evidence of Chagas infection (any combination of 2 positive tests) and that have one or more of the following:
Abnormal electrocardiogram with at least two components (complete RBBB or LBBB; left anterior or posterior fascicular block; ventricular premature beat; first degree atrioventricular [AV] block; Mobitz type I AV block; sinus bradycardia; primary ST-T changes; abnormal Q waves; low voltage QRS; or atrial fibrillation);
Abnormal ECG (Mobitz type II, advanced or third degree AV block);
Increased cardiothoracic ratio (> 0.50);
Complex ventricular arrythmias on 24 hour ambulatory ECG monitoring;
Evidence of regional wall motion abnormality or reduced global left ventricular systolic function or increased left ventricular and diastolic diameter on 2D-Echo.

Exclusion Criteria:

Patients will be excluded if having:

NYHA heart failure class IV or decompensated heart failure
Evidence of concomitant coronary artery disease (CAD) or other etiology of dilated cardiomyopathy
Previous treatment with antitrypanosomal agents or an accepted indication for antiparasitic therapy
Inability to comply with follow-up visits
History of severe alcohol abuse within 2 years
Known chronic renal or hepatic insufficiency or hepatic insufficiency
Pregnancy or breast feeding
Megaesophagus with swallowing impairment
Other severe disease significantly curtailing life expectancy
No Results Posted